- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05950191
LLIN Evaluation in Uganda Project (LLINEUP3)
January 15, 2026 updated by: University of California, San Francisco
LLIN Evaluation in Uganda Project (LLINEUP3): Impact of Long-lasting Insecticidal Nets (LLINs) Treated With Chlorfenapyr Plus Pyrethroid vs LLINs Treated With Piperonyl Butoxide Plus Pyrethroid on Malaria Incidence in Uganda: a Cluster-randomised Trial
In Uganda, the National Malaria Control Division (NMCD) and implementing partners are planning to deliver long-lasting insecticidal nets (LLINs) nationwide, through a mass distribution campaign in 2023.
LLINs will be distributed free-of-charge to all Ugandan households, aiming to achieve universal coverage.
LLINs treated with a pyrethroid insecticide plus chlorfenapyr (PermaNet Dual, Vestergaard) and LLINs treated with a pyrethroid insecticide plus PBO (PermaNet 3.0, Vestergaard) will be distributed as part of this distribution campaign, presenting an opportunity to rigorously evaluate and compare these two LLINs at scale across Uganda.
In collaboration with the MOH, this cluster-randomised trial will compare the impact of LLINs combining chlorfenapyr with a pyrethroid to LLINs combining PBO with a pyrethroid into Uganda's 2023 LLIN distribution campaign, as was done successfully at the time of the last LLIN distribution campaign conducted in 2020-21.
A major strength of this trial is the use of malaria incidence as the primary outcome measure.
Incidence of malaria, defined as the number of symptomatic cases of malaria occurring in a population at risk over time, is the gold standard for assessing malaria burden.
However, cluster-randomised trials using malaria incidence as the primary outcome typically involve study cohorts and are very expensive and logistically challenging.
The novel approach for measuring malaria incidence is to utilize data collected routinely at health facilities.
By defining target areas around health facilities and collecting data on the location of residence of patients diagnosed with malaria, this study will be able to generate longitudinal measures of malaria incidence at an unprecedented scale across Uganda as done in the LLINEUP2 trial (NCT04566510).
These results will inform policies and programmes for malaria and potentially provide evidence to support widescale deployment of dual AI chlorfenapyr-pyrethroid LLINs.
This study, the first evaluating PermaNet Dual LLINs, will also provide evidence for a second in class chlorfenapyr net, a potential tool to be added to the malaria control tool kit.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a cluster-randomised trial to evaluate the impact of long-lasting insecticidal nets (LLINs) distributed in Uganda through the 2023 national universal coverage campaign.
A cluster has been defined as the target area surrounding an MRC.
A total of 24 clusters will be included in the study, covering 20 moderate-high malaria burden districts in Uganda.
Clusters have been randomised in a 1:1 ratio to receive one of two types of LLINs: (1) chlorfenapyr-pyrethroid LLINs (PermaNet Dual, n=12) or (2) PBO-pyrethroid LLINs (PermaNet 3.0, n=12).
The intervention, including delivery of the LLINs and social and behaviour change communication (SBCC), will be led by the Ugandan NMCD and other stakeholders.
Currently, LLINs are scheduled to be distributed in the study areas during waves 5 and 6 from September to October 2023 as part of the national LLIN distribution campaign.
The evaluation of the intervention will include: 1) health facility surveillance at the participating MRCs to generate continuous estimates of malaria incidence for each MRC target area; 2) cross-sectional community surveys at 12- and 24-months post-LLIN distribution to gather information on parasite prevalence, anaemia prevalence, net ownership, coverage, and use, 3) entomology surveys at 12 and 24 months to gather information on vector density.
The primary outcome of the trial will be malaria incidence as estimated using the health facility surveillance.
Study Type
Interventional
Enrollment (Actual)
215903
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kampala, Uganda
- Infectious Diseases Research Collaboration
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Household Survey
Inclusion Criteria:
- At least one adult aged 18 years or older present
- Adult is a usual resident who slept in the sampled household on the night before the survey
- Agreement of the adult resident to provide informed consent for the household and entomology survey
Exclusion Criteria:
- Dwelling destroyed or not found
- Household vacant
- No adult resident home on more than 3 occasions
Clinical Survey
Inclusion Criteria:
- Usual resident who was present in the sampled household on the night before the survey
- Agreement of adult or parent/guardian (of children) to provide informed consent
- Agreement of child aged 8 years or older to provide assent
Exclusion Criteria:
1. Resident not home on day of survey
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PermaNet Dual
long lasting insecticidal nets with chlorfenapyr-pyrethroid
|
Next-generation bed net combining insecticides with different modes of action
The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC).
SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials.
Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
|
|
Active Comparator: PermaNet 3.0
long lasting insecticidal nets with PBO-pyrethroid
|
The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC).
SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials.
Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
Next-generation bed net combining an insecticide with a synergist
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of cases of laboratory-confirmed malaria diagnosed at the MRC among patients residing in the target area
Time Frame: 24-months follow up
|
malaria incidence: number of cases divided by the total population of the target area
|
24-months follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of parasitaemia
Time Frame: 24-months following LLIN distribution
|
Proportion of blood smears positive for parasites by microscopy in individuals of all ages at the time of cross-sectional surveys
|
24-months following LLIN distribution
|
|
Proportion of households that owned at least one LLIN
Time Frame: 24-months following LLIN distribution
|
Proportion of households with at least one LLIN at the time of cross-sectional surveys
|
24-months following LLIN distribution
|
|
Number of female anopheles mosquitoes collected per household at the time of cross-sectional surveys
Time Frame: 24-months following LLIN distribution
|
Vector density
|
24-months following LLIN distribution
|
|
Prevalence of anemia
Time Frame: 24-months following LLIN distribution
|
Proportion of children aged 2-4 years with haemoglobin < 11 g/dL at the time of cross-sectional surveys
|
24-months following LLIN distribution
|
|
Proportion of households that owned at least one LLIN for every two occupants
Time Frame: 24-months following LLIN distribution
|
Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys
|
24-months following LLIN distribution
|
|
Proportion of household residents who slept under an LLIN the previous night
Time Frame: 24-months following LLIN distribution
|
Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys
|
24-months following LLIN distribution
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Grant Dorsey, MD, PhD, University of California, San Francisco
- Principal Investigator: Moses Kamya, MBChB, MMed, PhD, Makerere University; Infectious Diseases Research Collaboration
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 27, 2023
Primary Completion (Actual)
December 31, 2025
Study Completion (Actual)
December 31, 2025
Study Registration Dates
First Submitted
July 10, 2023
First Submitted That Met QC Criteria
July 10, 2023
First Posted (Actual)
July 18, 2023
Study Record Updates
Last Update Posted (Actual)
January 20, 2026
Last Update Submitted That Met QC Criteria
January 15, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LLINEUP3
- U19AI089674 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
Medicines for Malaria VentureSwiss Tropical & Public Health Institute; Rinda Ubuzima, Rwanda; Swiss BioQuant; ACE ResearchNot yet recruitingMalaria | Malaria Infection | Malaria Prophylaxis | Malaria (Plasmodium Falciparum) | Malaria Falciparum | Malaria Parasitaemia | Malaria PreventionRwanda
-
Noguchi Memorial Institute for Medical ResearchMedical Research Center Unit The Gambia (MRCG)RecruitingMalaria Infection | Malaria Asymptomatic Parasitaemia | Malaria Falciparum | Malaria TransmissionGhana
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsWithdrawnPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLaos
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
PATHLiverpool School of Tropical Medicine; Centre national de recherche et de formation...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; Liverpool School of Tropical Medicine; Federal Ministry...Unknown
-
University of California, IrvineCompletedLLIN, PBO LLIN, IRS, LarvicidingUnited States, Kenya
-
PATHLiverpool School of Tropical Medicine; University of Rwanda; Rwanda Biomedical...Completed
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID); Mbarara University... and other collaboratorsActive, not recruitingMalaria Infection | Malaria FalciparumUganda
-
London School of Hygiene and Tropical MedicineCompletedMalaria | AnaemiaTanzania
-
University of California, San FranciscoLondon School of Hygiene and Tropical Medicine; University of Texas Southwestern... and other collaboratorsCompleted